10 Things Biotech CEOs Wish They Had Decided Three Years Earlier

By the time you have a commercial team, the decisions that matter most have already been made. That’s the part that keeps CEOs up at night: the fear of making a wrong call today and not discovering it until years from now, when it’s too late to unwind and the cost is enormous. These are the choices worth surfacing while they’re still cheap to change.

1. Indication sequence.

Which indication you lead with sets your evidence, your competition, and your story. Lead with the wrong one and it can permanently cap your commercial potential.

2. The target product profile.

The profile you set in development is what you’ll live with commercially for years. It drives what you can eventually claim, and what you can’t add back later.

3. Which asset gets the next dollar.

Portfolio prioritization is a commercial decision wearing a finance decision’s clothes. The asset you starve may be the one with the clearest path to a business.

4. How the pivotal trial is designed.

Endpoints, comparator, and population either support your commercial story or leave it with nothing to stand on. A trial that reads out positively can still fail to prove what the market needs to hear.

5. The addressable population you assumed.

The prevalence number in the early model is rarely the number you can reach in the real world. If you build the plan on the biggest possible market, you’ll be unprepared when you run into all of the things that cut it down in reality.

6. The decisions no one labeled commercial.

The most expensive commercial decisions are the ones no one realized were commercial. They get made by teams focused on the science, with no one accountable for what the choice does to the business.

7. Everything filed under “we’ll figure that out later.”

That might be the most expensive sentence in biotech. Later has a cost, and it compounds into a ceiling on what any launch can achieve.

8. What you decided by default.

Defaulting is still deciding. It’s just deciding without knowing you did, and those are the calls that surprise you years later.

9. When to act without certainty.

You’ll usually have to make the biggest decisions before you have certainty. Waiting for it is a choice in and of itself, and usually the costly one.

10. The question underneath all of it.

It all comes down to whether you made the right calls while they were still cheap to make. The best launches I’ve seen weren’t rescued by great execution. They were made close to inevitable by good decisions years earlier.

Most of these can’t be fully resolved this early. But every one of them has to be surfaced early, named as commercial, and decided on purpose instead of by default. What’s the “we’ll figure it out later” in your pipeline right now?